Merit Medical To See Sustained Revenue Growth Despite Macro Headwinds, Bullish Analyst Says

  • Needham analyst Mike Matson reiterated a Buy rating on the shares of Merit Medical Systems Inc MMSIraising the price target to $90 from $84.
  • Merit Medical is executing "well on its strategy" despite macro headwinds, and the analyst anticipates sustained strong revenue growth, margin improvement, and free cash flow.
  • Noting the bull case assumptions, Matson expects organic revenue growth to accelerate into the high-single digits or better, driven by recent acquisitions and new product launches, resulting in significant operating margin improvement.
  • The analyst believes that the company's revenue growth will return to the mid-single digits or better and EPS growth will return to 15%+. In 1Q23, reported revenue grew 8% Y/Y to $297.6 million.
  • Based on the above, the analyst raised the 2023 and 2024 EPS estimates to $2.90 from $2.85 and to $3.21 from $3.11, respectively.
  • Price Action: MMSI shares closed higher by 5.27% at $81.76 on Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorEquitiesNewsPrice TargetReiterationMarketsAnalyst RatingsGeneralBriefsExpert Ideas
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!